Twist Bioscience Corporation (Nasdaq: TWST) today announced the enhanced Twist Clonal Genes product line with the expansion of preparation quantities, delivery formats, buffer options, and tube and plate options. Customers can now access larger amounts of DNA in the format suitable for their specific research needs.
“Leveraging our ability to write DNA at scale, we believe the extension of our clonal genes offers our customers a one-stop shop for their pharmaceutical and biotechnology research and a more robust depth of products to complete their research,” said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. “We remain committed to meeting the increasing needs of the research community, as now, more than ever, synthetic biology tools are needed to identify critical targets and develop new therapeutics to treat COVID-19 and also the many other devastating diseases that did not slow down in the face of the global pandemic.”
Clonal genes are full-length genes cloned into a plasmid, a molecule that can replicate independent of standard genetic replication in the chromosomes. Clonal genes can be used in a wide range of studies including multiple areas of the drug discovery and development process. Clonal genes are also used in a wide array of pharmaceutical and biotechnology research including identifying the target or physiological function of a particular gene, developing vaccines and diagnostic tests, as well as discovering and developing novel therapeutics to treat disease.
About Twist Bioscience Clonal Genes
Twist Bioscience is transforming gene synthesis, which is a process at the core of synthetic and molecular biology. Leveraging its silicon-based DNA writing platform, Twist significantly increases gene synthesis throughput and scalability, while also reducing turnaround time and price per base. Twist’s Clonal Genes offering provides flexibility in the volume and format desired. Twist verifies every Clonal Gene through NGS to ensure the perfect cloned gene every time. With Twist’s new offering researchers are now able to access in various sizes, from two micrograms up to one milligram of DNA, delivered from 11 business days for all order sizes.
About Twist Bioscience Corporation
Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary technology that pioneers a new method of manufacturing synthetic DNA by “writing” DNA on a silicon chip. Twist is leveraging its unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next-generation sequencing (NGS) preparation, and antibody libraries for drug discovery and development. Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery. Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.
Legal Notice Regarding Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained herein, including without limitation Twist’s ability to deliver its DNA preparations to its customers, are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist Bioscience’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, Twist’s ability to deliver clonal genes from 11 business days for all order sizes; the risks and uncertainties of the ability to attract new customers and retain and grow sales from existing customers; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology could make the products Twist Bioscience is developing obsolete or non-competitive; uncertainties of the retention of a significant customer; risks of third party claims alleging infringement of patents and proprietary rights or seeking to invalidate Twist Bioscience’s patents or proprietary rights; and the risk that Twist Bioscience’s proprietary rights may be insufficient to protect its technologies. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist Bioscience’s business in general, see Twist Bioscience’s risk factors set forth in Twist Bioscience’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on February 10, 2020. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist Bioscience specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.